ReviewFrontiers in neuroscience2026
Exploring the neuroprotective potential of ligustrazine: a preclinical meta-analysis and machine learning perspective on cerebral ischemia-reperfusion injury.
Review in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the efficacy of ligustrazine in treating cerebral ischemia-reperfusion (I/R) injury and construct a preclinical evidence framework by meta-analysis and machine learning. Methods: A systematic search was conducted for preclinical studies published in PubMed, Embase, Web of Science, and the Cochrane Library up to June 25, 2024. The inclusion criteria encompassed preclinical animal studies pertinent to the topic. Data extraction was performed independently by two individuals, Stata 17.0 software was used for quantitative analysis, R (version 4.3.3) and Python (version 3.11.4) were used for machine learning with neurological function score as the dependent variable. Results: A total of 23 articles were included, involving 381 animals in the meta-analysis and 321 animals in the machine learning component. Ligustrazine significantly improved neurofunctional scores (NFS) [Longa criteria, Conclusion: The combination of meta-analysis and machine learning in this study not only confirms that ligustrazine is effective in reducing cerebral I/R injury, but also provides a framework for elucidating the preclinical intervention variables, thus offering novel insights for optimizing preclinical strategies of ligustrazine in cerebral I/R injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.